指南与共识头颈与中枢神经肿瘤支持与姑息治疗

现代化临床试验入组标准:ASCO-FCR脑转移工作组的推荐

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group.
指南 / 共识 · J Clin Oncol · 2017-10-02

ASCO-FCR脑转移工作组通过文献检索与多利益相关方研讨会形成共识,将脑转移患者分为治疗后稳定、活动性和软脑膜病变三类,并推荐在多数情况下纳入治疗后稳定者,对活动性者提出关键考量框架,对软脑膜病变建议在预期CNS活性且与疾病类型相关时设置独立队列。

要点

  • 治疗后稳定脑转移患者在多数情况下应被鼓励纳入临床试验。
  • 活动性(新发和/或进展)脑转移患者需按关键考量框架评估后决定是否纳入。
  • 软脑膜病变患者在预期CNS活性且与特定疾病类型相关时,推荐在早期和后期试验中设独立队列。

核心结论

  • 在许多情况下扩大入组标准以更包容脑转移患者是合理的,并可能加速这一高临床需求领域有效疗法的开发。

研究设计与样本

  • 2016年经文献检索和系列电话会议后召开多利益相关方研讨会,工作组聚焦制定脑转移患者纳入临床试验的共识推荐,并基于研讨会意见进一步细化和最终确定指南。

主要发现

  • 工作组识别出三类关键人群:治疗后/稳定脑转移(入组时CNS病灶影像学稳定)、活动性脑转移(入组时新发和/或进展)、软脑膜病变。
  • 对于治疗后/稳定脑转移患者,工作组在多数情况下鼓励纳入临床试验。
  • 针对活动性脑转移患者,工作组制定了关键考量框架。
  • 对于软脑膜病变患者,若预期有CNS活性且与特定疾病类型相关,推荐在早期和后期试验中均设置独立队列。

关键数值与推荐

  • 治疗后/稳定脑转移定义为已接受过脑转移 prior 治疗且入组时CNS疾病影像学稳定。
  • 活动性脑转移定义为入组时新发和/或进展的脑转移。
  • 软脑膜病变患者推荐在早期和后期试验中设独立队列,条件为预期CNS活性且与特定疾病类型相关。

临床怎么用

  • 在多数情况下应鼓励将治疗后/稳定脑转移患者纳入临床试验。
  • 对活动性脑转移患者,可参照工作组制定的关键考量框架评估入组。
  • 对软脑膜病变患者,若预期CNS活性且与特定疾病类型相关,可在早期和后期试验中设置独立队列。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Broadening trial eligibility to improve accrual and access and to better reflect intended-to-treat populations has been recognized as a priority. Historically, patients with brain metastases have been understudied, because of restrictive eligibility across all phases of clinical trials. Methods In 2016, after a literature search and series of teleconferences, a multistakeholder workshop was convened. Our working group focused on developing consensus recommendations regarding the inclusion of patients with brain metastases in clinical trials, as part of a broader effort that encompassed minimum age, HIV status, and organ dysfunction. The working group attempted to balance the needs of protecting patient safety, facilitating access to investigational therapies, and ensuring trial integrity. On the basis of input at the workshop, guidelines were further refined and finalized. Results The working group identified three key populations: those with treated/stable brain metastases, defined as patients who have received prior therapy for their brain metastases and whose CNS disease is radiographically stable at study entry; those with active brain metastases, defined as new and/or progressive brain metastases at the time of study entry; and those with leptomeningeal disease. In most circumstances, the working group encourages the inclusion of patients with treated/stable brain metastases in clinical trials. A framework of key considerations for patients with active brain metastases was developed. For patients with leptomeningeal disease, inclusion of a separate cohort in both early-phase and later-phase trials is recommended, if CNS activity is anticipated and when relevant to the specific disease type. Conclusion Expanding eligibility to be more inclusive of patients with brain metastasis is justified in many cases and may speed the development of effective therapies in this area of high clinical need.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lin NU, Prowell T, Tan AR, et al. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group. J Clin Oncol. 2017. PMID: 28968165. doi:10.1200/JCO.2017.74.0761

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。